Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis.

× No keyword cloud information.

13 in total

Review 1. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors: Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal: Chest Date: 2012-02 Impact factor: 9.410

2. Treatment with argatroban in one haemodialysed patient with a heparin-induced thrombocytopenia and thrombotic complications.

Authors: Adriano Alatri; Marina Foramitti; Oriana Paoletti; Anke Zimmermann; Sophie Testa
Journal: Intern Emerg Med Date: 2010-02-23 Impact factor: 3.397

Review 3. What are the anticoagulation options for intermittent hemodialysis?

Authors: Andrew Davenport
Journal: Nat Rev Nephrol Date: 2011-07-05 Impact factor: 28.314

4. Anti-PF4/heparin antibodies are associated with arteriovenous fistula thrombosis in non-diabetic hemodialysis patients.

Authors: Yueh-Feng Tsai; Chien-An Chen; Chieh Kuo; Kao-Chang Lin
Journal: Clin Exp Nephrol Date: 2011-11-01 Impact factor: 2.801

5. Significant association of anti-platelet factor 4/heparin antibody with cardiovascular disease in hemodialysis patients: a longitudinal 7-year study.

Authors: Chi-Chu Liu; Li-Ping Chou; Tsang-Shan Chen; Chien-An Chen; Yueh-Feng Tsai
Journal: Int Urol Nephrol Date: 2018-10-15 Impact factor: 2.370

6. CD62P and P10 as predictive markers for assessing the efficacy of hemodialysis in treating end-stage renal disease.

Authors: Ji-Rong Yu; Feng-Mei Wang; Sheng-Chun Xu; Min Gao
Journal: J Clin Lab Anal Date: 2018-10-15 Impact factor: 2.352

Review 7. Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis.

Authors: Jenny I Shen; Wolfgang C Winkelmayer
Journal: Am J Kidney Dis Date: 2012-05-05 Impact factor: 8.860

Review 8. Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments.

Authors: Andrew Davenport
Journal: Pediatr Nephrol Date: 2012-02-29 Impact factor: 3.714

9. The clinical significance and risk factors of anti-platelet factor 4/heparin antibody on maintenance hemodialysis patients: a two-year prospective follow-up.

Authors: Delong Zhao; Xuefeng Sun; Li Yao; Hongli Lin; Jijun Li; Jiuyang Zhao; Zhimin Zhang; Lide Lun; Jianrong Zhang; Mingxu Li; Qi Huang; Yang Yang; Shimin Jiang; Yong Wang; Hanyu Zhu; Xiangmei Chen
Journal: PLoS One Date: 2013-04-30 Impact factor: 3.240

10. Anti-neutrophil cytoplasmic antibody-associated vasculitis accompanied by type II heparin-induced thrombocytopenia resulting in asymptomatic cerebral infarction: a case report.

Authors: Yoshitaka Furuto; Mariko Kawamura; Jumpei Yamashita; Takahiro Yoshikawa; Akio Namikawa; Rei Isshiki; Hiroko Takahashi; Yuko Shibuya
Journal: BMC Nephrol Date: 2021-06-14 Impact factor: 2.388